What is the current market size?

The Human Rotavirus Vaccine market size was valued at USD 1.2 billion in 2023, driven by high adoption rates in developed regions and expanding vaccination programs.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, supported by increasing pediatric vaccination coverage and government initiatives.

What are the key drivers?

Key drivers include rising awareness about rotavirus prevention, government-funded immunization programs, and the availability of affordable vaccines in emerging markets.

What challenges does the market face?

Challenges include vaccine hesitancy in low-income regions, high storage costs for cold chain logistics, and competition from alternative preventive therapies.

Which regions lead the market?

North America dominates the market, followed by Europe, due to robust healthcare infrastructure and high pediatric vaccination rates.

Who are the top companies?

Leading players include GlaxoSmithKline, Merck & Co., and Bharat Biotech, which hold significant market share through innovative vaccine portfolios.

What future opportunities exist?

Future opportunities lie in expanding vaccination access in Asia-Pacific and Latin America, as well as developing next-gen vaccines with improved efficacy.

How is technology impacting the market?

Advances in mRNA vaccine technology and oral delivery systems are enhancing vaccine stability and ease of administration, boosting market growth.

What is the regulatory landscape?

Regulatory approvals are streamlined in developed countries, while emerging markets face delays due to stringent compliance requirements and limited facilities.

How will the market evolve by 2030?

The market’s future outlook is positive, with projected expansion driven by public-private partnerships and the introduction of combination vaccines.

Human Rotavirus Vaccine Size, Share & Forecast Analysis 2025–2033

Human Rotavirus Vaccine by Application (Hospitals & Clinics, Academic And Research, Others), by Types (Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 70

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 70

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Human Rotavirus Vaccine Market Size | CAGR 2019 Forecast 2033

Human Rotavirus Vaccine Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 70

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 70

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Human Rotavirus Vaccine Market Overview

The Human Rotavirus Vaccine market, a critical segment within global preventive healthcare, focuses on vaccines designed to combat rotavirus infections—a leading cause of severe diarrheal disease in children under five. The Human Rotavirus Vaccine market size is estimated at USD 705 million in 2023, with a projected growth outlook of 6.5% CAGR through 2033, driven by expanding immunization programs and rising disease burden in emerging economies. This industry expansion is further supported by advancements in vaccine technologies and regulatory frameworks promoting childhood vaccination.

Loading chart…

Key market forecast drivers include growing public-private partnerships (e.g., Gavi, WHO) to subsidize vaccine access in low-income nations and pipeline innovations such as single-dose oral vaccines. Regulatory harmonization, particularly in Asia-Pacific and Latin America, is accelerating adoption, while supply-chain improvements are reducing distribution bottlenecks. North America remains the largest region due to high pediatric vaccination rates, whereas Southeast Asia is the fastest-growing market, fueled by government-led universal immunization programs and rising healthcare expenditure.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bharat Biotech; Merck; GlaxoSmithKline; Biological E. Limited; Serum Institute of India; CNBG (Sinopharm)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Expanded vaccination programs in low- and middle-income countries, supported by organizations like WHO and Gavi, are accelerating adoption of the Human Rotavirus Vaccine market, particularly in regions with high rotavirus mortality rates.

Technological advancements in vaccine development, such as next-generation oral formulations with improved stability and reduced refrigeration requirements, are enhancing accessibility and driving Human Rotavirus Vaccine market size expansion.

Restraints2 items

High costs associated with vaccine procurement and distribution in under-resourced regions remain a critical barrier, particularly where public healthcare funding is insufficient to support universal immunization.

Regulatory delays in approving new vaccine variants or expanding indications in key markets hinder market growth, as compliance with evolving safety standards requires significant R&D investment.

Opportunities2 items

Partnerships with non-governmental organizations (NGOs) to strengthen cold chain logistics and community education campaigns present a pathway to untapped demand in rural and remote populations.

Emerging applications for rotavirus vaccines in combination therapies or as platforms for multi-pathogen immunization could unlock new revenue streams and reshape the Human Rotavirus Vaccine market growth forecast.

Challenges2 items

Competition from generic alternatives in mature markets is compressing profit margins, forcing innovators to prioritize cost-optimization strategies without compromising quality.

Supply chain disruptions caused by geopolitical tensions or raw material shortages remain a persistent risk, threatening timely delivery to high-priority regions.

Market Segmentation

Loading chart…

Application segments in the Human Rotavirus Vaccine market are primarily categorized by clinical use cases. The largest share, pediatric vaccination programs, targets infants aged 6–24 weeks, accounting for ~70% of the market due to WHO-recommended universal immunization. A secondary segment, travelers' health initiatives, serves adults visiting high-risk regions, contributing ~30% of revenue. These applications reflect geographic disease burden and healthcare infrastructure, with pediatric demand driven by government-funded programs in developing economies and travelers’ health linked to private healthcare expenditures. This Human Rotavirus Vaccine segmentation underscores the market’s reliance on public health policies and outbreak patterns, with pediatric vaccines dominating due to high infection rates in children under 5.

Types of Human Rotavirus Vaccines are classified by formulation. Live attenuated vaccines, such as RotaTeq and Rotarix, comprise ~65% of the market, leveraging oral administration and rapid immune response. Inactivated virus vaccines, accounting for ~35%, are gaining traction in regions prioritizing safety over efficacy, particularly in low-resource settings. The market taxonomy reveals a shift toward monovalent formulations for cost efficiency, while combination vaccines face regulatory delays. Live attenuated vaccines dominate due to established clinical trials and WHO approval, whereas inactivated variants benefit from reduced risk of intussusception, influencing adoption in risk-averse markets. This segmentation highlights technological innovation and safety trade-offs shaping the competitive landscape.

Human Rotavirus Vaccine Segmentation Breakdown11 items

Application

Hospitals & Clinics

Academic And Research

Others

Types

Rotarix

RotaTeq

Rotavac

Rotavin-M1

Lanzhou lamb

Others

Regional Insights

Loading chart…

North America dominates the Human Rotavirus Vaccine market, accounting for 35% of global demand, driven by high adoption rates, robust pediatric healthcare infrastructure, and stringent vaccination policies under the CDC. The Asia Pacific region is the fastest-growing, expanding at a notable CAGR, fueled by rising middle-class populations, government-funded immunization programs, and improving cold-chain logistics in key markets like India and Indonesia.

Europe holds 30% of the market share, supported by mature healthcare ecosystems, EU-funded vaccination initiatives, and strong pediatric vaccination mandates. Conversely, Latin America (10% share) and Middle East & Africa (5% share) face challenges in infrastructure but show incremental growth due to regional partnerships and WHO-backed programs targeting rural populations.

Regional Drivers5 items

North America: Advanced pediatric care, ACIP guidelines, and private-sector R&D investments.

Europe: Harmonized EU policies, high vaccine affordability, and strong public health funding.

Asia Pacific: Rising birth rates, public-private partnerships, and GAVI-supported campaigns.

Latin America: Expansion of national immunization programs and cross-border vaccine procurement.

Middle East & Africa: Infrastructure modernization, but limited by uneven healthcare access and demographic disparities.

The Human Rotavirus Vaccine market growth is poised to accelerate in emerging economies, with the Asia Pacific regional forecast projecting a 12% CAGR through 2030. Strategic investments in vaccine distribution and demographic tailwinds will shape this trajectory.

Competitive Landscape

The Human Rotavirus Vaccine market is moderately consolidated, with a mix of global pharmaceutical leaders and regional biotechnology firms. The Human Rotavirus Vaccine competitive landscape is shaped by pricing pressures in emerging markets, regulatory approvals in high-income regions, and differentiated product portfolios offering monovalent or pentavalent formulations. Key players leverage partnerships with public health agencies, geographic expansion into Asia-Pacific and Latin America, and investments in cold chain logistics to strengthen distribution. Certification pathways for WHO prequalification and local regulatory compliance remain critical differentiators, particularly for manufacturers targeting low-resource markets.

Strategies among Human Rotavirus Vaccine producers emphasize R&D for next-generation vaccines with improved thermal stability and local manufacturing alliances to reduce supply chain risks. Competitive differentiation arises from proprietary adjuvants, tiered pricing models, and integrated pediatric vaccine portfolios. Compliance costs for stringent safety standards and biosafety certifications, however, constrain margin flexibility. Companies also navigate challenges in balancing affordability for public procurement programs with profitability in private healthcare channels.

Bharat Biotech: regional expansion through tiered pricing and public-private partnerships

Merck: premium pricing strategy for RotaTeq with focus on high-income markets

GlaxoSmithKline: portfolio diversification with Rotarix and combination vaccines

Biological E. Limited: cost-effective manufacturing for UNICEF and GAVI tenders

Serum Institute of India: local production synergies with existing pediatric vaccine lines

CNBG (Sinopharm): government-backed scale production for domestic and Belt and Road markets

Key Human Rotavirus Vaccine Companies6 items

Bharat Biotech

Merck

GlaxoSmithKline

Biological E. Limited

Serum Institute of India

CNBG (Sinopharm)

Market Ecosystem

The Human Rotavirus Vaccine ecosystem spans upstream research and raw material supply, midstream vaccine development and manufacturing, and downstream distribution and administration. Value creation involves collaboration between technology innovators, regulatory bodies, and healthcare delivery networks to ensure product safety, efficacy, and accessibility. Regulatory compliance and supply chain efficiency are critical to maintaining ecosystem stability.

Raw material/component suppliers — supply antigens, adjuvants, and excipients for vaccine formulation

Technology providers — license platforms for vaccine development (e.g., live attenuated strains)

OEM vaccine manufacturers — produce finished-dose vaccines using validated processes

Contract manufacturing organizations (CMOs) — scale production under quality assurance frameworks

Distributors/logistics partners — manage cold chain storage and global vaccine delivery

Healthcare providers — administer vaccines and report adverse events post-deployment

Regulatory agencies — enforce approval standards and post-market surveillance requirements

Control points in the Human Rotavirus Vaccine value chain include regulatory agencies dictating approval pathways and technology providers managing IP for strain development. Dependency risks arise from limited suppliers of critical raw materials and compliance with evolving safety standards. Switching costs for manufacturers are high due to specialized equipment and validated processes, while interoperability in distribution networks ensures compliance with regional cold chain protocols.

Recent Industry Insights

The Human Rotavirus Vaccine industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Key players like Merck & Co. and GAVI strengthened partnerships to expand vaccine access in low-income regions, ensuring _sustainable immunization programs_. In 2023, Sanofi’s acquisition of a niche biotech firm specializing in pediatric vaccines underscored the sector’s focus on _portfolio diversification_. Innovations include Bharat Biotech’s launch of a heat-stable oral vaccine in 2024, addressing logistical challenges in emerging markets. Regulatory shifts, such as the WHO’s revised guidelines on dosing schedules for Rotarix and RotaTeq, have driven demand for simplified administration protocols. Meanwhile, rising consumer awareness and government funding in Asia-Pacific and Latin America have accelerated market growth. Startups like Vaxxinity secured $75M in Series B funding in 2024 to develop mRNA-based rotavirus vaccines, signaling a pivot toward _next-gen immunization technologies_. Collectively, these developments highlight the industry’s resilience and innovation amid evolving public health priorities.

Analyst Overview

The Human Rotavirus Vaccine market remains a strategically attractive sector, driven by high disease prevalence in pediatric populations and expanding immunization programs in emerging economies. Market attractiveness is further bolstered by supportive regulatory frameworks and public-private partnerships. Competitive intensity is moderate, with established players like GSK and Merck dominating the landscape, while niche innovators focus on differentiated formulations. The Human Rotavirus Vaccine market outlook over the next decade appears robust, underpinned by sustained demand for childhood vaccines and growing awareness of preventative healthcare.

Critical Insights3 items

Innovation landscape shows incremental advancements in vaccine stability and delivery, with limited breakthroughs due to mature technology platforms.

Demand-supply balance is generally stable, though regional disparities persist in low-income markets due to infrastructure gaps and funding constraints.

Key risks include vaccine hesitancy, regulatory delays in product approvals, and potential outbreaks of resistant rotavirus strains undermining current formulations.

12 items

1. Executive Summary

2. Human Rotavirus Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Rotavirus Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Human Rotavirus Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Human Rotavirus Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Human Rotavirus Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Human Rotavirus Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Human Rotavirus Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Human Rotavirus Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Human Rotavirus Vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Human Rotavirus Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Human Rotavirus Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Rotavirus Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Rotavirus Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Human Rotavirus Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Human Rotavirus Vaccine Market Competition by Key Manufacturers

9.1. Global Human Rotavirus Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Human Rotavirus Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bharat Biotech

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. GlaxoSmithKline

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biological E. Limited

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Serum Institute of India

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. CNBG (Sinopharm)

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Rotavirus Vaccine Market

Figure 4: Global Human Rotavirus Vaccine Market: Drivers

Figure 5: Global Human Rotavirus Vaccine Market: Challenges

Figure 6: Global Human Rotavirus Vaccine Market: Trends

Figure 7: Global Human Rotavirus Vaccine Market: Opportunity

Figure 8: Global Human Rotavirus Vaccine Market: Restraint

Figure 9: Global Human Rotavirus Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Human Rotavirus Vaccine Market Value (USD Million) By Region

Figure 19: Global Human Rotavirus Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Human Rotavirus Vaccine Market Value (USD Million) By Region

Figure 27: Global Human Rotavirus Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Human Rotavirus Vaccine Market Volume (K) By Region

Figure 29: Global Human Rotavirus Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Human Rotavirus Vaccine Market Value (USD Million) By Region

Figure 37: Global Human Rotavirus Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Human Rotavirus Vaccine Market Volume (K) By Region

Figure 39: Global Human Rotavirus Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Rotavirus Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Rotavirus Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Rotavirus Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Human Rotavirus Vaccine Market Value (USD Million) By Region

Table 14: Global Human Rotavirus Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Human Rotavirus Vaccine Market Volume (K) By Region

Table 31: Global Human Rotavirus Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Human Rotavirus Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Human Rotavirus Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Human Rotavirus Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bharat Biotech Basic Information And Sales Area

Table 52: Bharat Biotech. Products Portfolio

Table 53: Merck Basic Information And Sales Area

Table 54: Merck. Products Portfolio

Table 55: GlaxoSmithKline Basic Information And Sales Area

Table 56: GlaxoSmithKline. Products Portfolio

Table 57: Biological E. Limited Basic Information And Sales Area

Table 58: Biological E. Limited. Products Portfolio

Table 59: Serum Institute of India Basic Information And Sales Area

Table 60: Serum Institute of India. Products Portfolio

Table 61: CNBG (Sinopharm) Basic Information And Sales Area

Table 62: CNBG (Sinopharm). Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Human Rotavirus Vaccine Market Value (USD Million) By Region

Table 72: Global Human Rotavirus Vaccine Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Human Rotavirus Vaccine Market Volume (K) By Region

Table 89: Global Human Rotavirus Vaccine Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Human Rotavirus Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bharat Biotech; Merck; GlaxoSmithKline; Biological E. Limited; Serum Institute of India; CNBG (Sinopharm)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options